Nav: Home

State-of-the-art HIV drug could curb HIV transmission, improve survival in India

April 30, 2018

An HIV treatment regimen already widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India by nearly three years and reduce the number of new HIV infections by 23 percent with minimal impact on the country's HIV/AIDS budget. The findings from an international team of investigators have been published online in the Journal of the International AIDS Society.

"This study is the first to show that, in India, changing current therapy to a dolutegravir-based regimen would be safer, save lives and prevent new infections - all without increasing the cost of care," said lead author Amy Zheng of the Massachusetts General Hospital (MGH) Medical Practice Evaluation Center in Boston.

Dolutegravir, developed by the HIV specialist company ViiV Healthcare, has been shown to have fewer side effects and be less likely to induce drug resistance than other currently available HIV drugs. It is currently recommended in North America and Europe as initial therapy for newly infected patients and is available in multiple African countries. A generic version has only recently become available in India.

The researchers used a widely-published mathematical model to project the survival and economic outcomes of adopting a dolutegravir-based regimen as first-line therapy by the Indian health system. Based on cost estimates from the Clinton Health Access Initiative, the analysis assumed the annual cost of the new drug would be $102 U.S. per patient, which is slightly higher than the $98 annual cost of current therapy in India. The team assessed the impact of a dolutegravir-based regimen on life expectancy, the number of new HIV transmissions, HIV care costs and the national Indian HIV budget over 2- and 5-year time horizons.

The results indicated that the new regimen would extend the life expectancy of people living with HIV by 2.8 years and prevent 13,000 new HIV infections over 5 years. Importantly, using dolutegravir as first-line treatment is likely to be cost-effective in 2 years and cost-saving over 5 years - that is, the clinical and public health benefits would be realized at no additional cost to the national government, compared with the costs of the current regimens. Adoption of dolutegravir-based treatment would likely reduce the number of patients who require a switch to more costly and less effective second- and third-line HIV therapies.

Study author Nagalingeswaran Kumarasamy, MD, chief medical officer of the Y.R. Gaitonde Centre for AIDS Research and Education in Chennai, India, says, "Given the size and scope of the HIV epidemic in India, making a dolutegravir-based regimen first-line therapy through the National AIDS Control Organization will provide tremendous benefit to our patients and to India as a whole."

In late 2017, two India-based pharmaceutical companies agreed to provide a generic, dolutegravir-based combination drug to several African countries for $75 per patient per year, a cost even lower than that of current HIV therapy in India. However, in spite of these new advances in HIV therapy in other nations, generic dolutegravir remains out of reach in India - both because of its current costs in that country and because it is not yet the standard therapy - a country in which more than 2 million people live with HIV, the world's third largest population with HIV.

"With India being the world's leading producer of generic HIV therapy, it only makes sense for the tremendous benefits of these therapies to become available to people with HIV in India," added study senior author Kenneth A. Freedberg, MD, MSc, of the MGH Medical Practice Evaluation Center.
-end-
Additional co-authors of the report are Mingshu Huang, PhD, and Rochelle Walensky, MD, MPH, MGH Medical Practice Evaluation Center; A. David Paltiel, PhD, MBA, Yale School of Public Health; Kenneth H. Mayer, MD, Beth Israel Deaconess Medical Center and the Fenway Institute, and Bharat B. Rewari, MD, World Health Organization. The study was supported by National Institute of Allergy and Infectious Diseases grants R01 AI058736 and R37 AI093269 and by the Steve and Deborah Gorlin MGH Research Scholar Award.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals, earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service and returned to the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Hiv Articles:

Defective HIV proviruses reduce effective immune system response, interfere with HIV cure
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30,000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published today by ECDC and the WHO Regional Office for Europe.
Smoking may shorten the lifespan of people living with HIV more than HIV itself
A new study led by researchers at Massachusetts General Hospital finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the US, potentially even more than HIV itself.
For smokers with HIV, smoking may now be more harmful than HIV itself
HIV-positive individuals who smoke cigarettes may be more likely to die from smoking-related disease than the infection itself, according to a new study published in the Journal of Infectious Diseases.
Patients diagnosed late with HIV infection are more likely to transmit HIV to others
An estimated 1.2 million people live with HIV in the United States, with nearly 13 percent being unaware of their infection.
The Lancet HIV: New HIV infections stagnating at 2.5 million a year worldwide
A major new analysis from the Global Burden of Disease 2015 study, published today in The Lancet HIV journal, reveals that although deaths from HIV/AIDS have been steadily declining from a peak in 2005, 2.5 million people worldwide became newly infected with HIV in 2015, a number that hasn't changed substantially in the past 10 years.
NIH scientists discover that defective HIV DNA can encode HIV-related proteins
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.
Study examines risk of HIV transmission from condomless sex with virologically suppressed HIV infection
Among nearly 900 serodifferent (one partner is HIV-positive, one is HIV-negative) heterosexual and men who have sex with men couples in which the HIV-positive partner was using suppressive antiretroviral therapy and who reported condomless sex, during a median follow-up of 1.3 years per couple, there were no documented cases of within-couple HIV transmission, according to a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue.
HIV vaccine design should adapt as HIV virus mutates
Researchers from UAB, Emory and Microsoft demonstrate that HIV has evolved to be pre-adapted to the immune response, worsening clinical outcomes in newly infected patients.
Charlie Sheen's HIV disclosure may reinvigorate awareness, prevention of HIV
Actor Charlie Sheen's public disclosure in November 2015 that he has the human immunodeficiency virus (HIV) corresponded with the greatest number of HIV-related Google searches ever recorded in the United States, according to an article published online by JAMA Internal Medicine.

Related Hiv Reading:

HIV Essentials 2017
by Paul E. Sax (Author), Calvin J. Cohen (Author), Daniel R. Kuritzkes (Author)

The world's leading experts provide all the 'essentials' needed to manage HIV patients in the office, on the ward, and in the ICU.

Completely revised and updated, HIV Essentials 2017 incorporates the latest clinical guidelines into a step-by-step guide to the diagnosis, evaluation, management, and prevention of HIV infection and its complications. Topics include: opportunistic infections and other HIV complications, treatment of HIV and pregnancy, antiretroviral drug summaries, post-exposure prophylaxis, as well as commercially available dosage forms for all ARVs. View Details


2018 ADULT HIV/AIDS TREATMENT POCKET GUIDE (2018 edition)
by John G Bartlett (Author), Paul A Pham (Author)

This HIV/AIDS summarizes National Clinical Guidelines with an attempt to achieve brevity, clarity and accuracy in guiding clinical decisions relevant to the management of adult patients with HIV/AIDS. This guide includes expanded drug-drug interactions tables, antiretroviral pictures tables, and summary of treatment guidelines. 

View Details


Fundamentals of HIV Medicine: (CME edition)
by American Academy of HIV Medicine (Compiler), W. David Hardy (Compiler)

Completely updated for 2017, Fundamentals of HIV Medicine is a comprehensive clinical care publication for the treatment of HIV/AIDS. Published by the American Academy of HIV Medicine, the book offers physicians, pharmacists, nurse practitioners, and other care providers the most up-to-date overview of the latest HIV treatments and guidelines plus online access to CME. The online access expires August 2018.

Embodying the AAHIVM's commitment to promoting uniform excellence in care of seropositive patients, Fundamentals of HIV Medicine 2017 empowers health... View Details


Living a Healthy Life with HIV
by Allison Webel RN Ph.D (Author), Kate Lorig DrPH (Author), Diana Laurent MPH (Author), Virginia González MPH (Author), Allen L. Gifford MD (Author), David Sobel MD MPH (Author), Marian Minor PT PhD (Author)

Completely updated to the current care guidelines from the Centers for Disease Control and elsewhere, this book addresses the current emphasis on managing medications for HIV treatment and many of the illnesses that commonly occur along with HIV. Combining the latest medical advice with the ideas of hundreds of people living with HIV, the book is helpful for adults living with HIV, and for friends, family members, and others who support anyone struggling with HIV. New additions to this edition include topics such as aging with HIV and coping with the emotions brought about by being a... View Details


100 Questions & Answers About HIV and AIDS
by Joel E. Gallant (Author)

Whether you're a newly diagnosed patient or a friend or relative of someone suffering from HIV or AIDS, this book can help. Offering both doctor and patient perspectives, 100 Questions & Answers About HIV and AIDS, Fourth Edition provides authoritative and practical answers to the most commonly asked questions by patients and their loved ones. What is the difference between HIV and AIDS? How can HIV infection be prevented? How do I find the right medical care?

Along with the answers to these and other questions, this book provides information on diagnosis, treatment, living with HIV... View Details


HIV & AIDS: A Very Short Introduction (Very Short Introductions)
by Alan Whiteside (Author)

In 2008 it was believed that HIV/AIDS was without doubt the worst epidemic to hit humankind since the Black Death. The first case was identified in 1981; by 2004 it was estimated that about 40 million people were living with the disease, and about 20 million had died. Yet the outlook today is a little brighter. Although HIV/ AIDS continues to be a pressing public health issue the epidemic has stabilised globally, and it has become evident it is not, nor will it be, a global issue. The worst affected regions are southern and eastern Africa. Elsewhere, HIV is found in specific, usually,... View Details


The Chimp and the River: How AIDS Emerged from an African Forest
by David Quammen (Author)

In this "frightening and fascinating masterpiece" (Walter Isaacson), David Quammen explores the true origins of HIV/AIDS.

The real story of AIDS―how it originated with a virus in a chimpanzee, jumped to one human, and then infected more than 60 million people―is very different from what most of us think we know. Recent research has revealed dark surprises and yielded a radically new scenario of how AIDS began and spread. Excerpted and adapted from the book Spillover, with a new introduction by the author, Quammen's hair-raising investigation tracks the... View Details


Taking Turns: Stories from HIV/AIDS Care Unit 371 (Graphic Medicine)
by MK Czerwiec (Author)

In 1994, at the height of the AIDS epidemic in the United States, MK Czerwiec took her first nursing job, at Illinois Masonic Medical Center in Chicago, as part of the caregiving staff of HIV/AIDS Care Unit 371. Taking Turns pulls back the curtain on life in the ward.

A shining example of excellence in the treatment and care of patients, Unit 371 was a community for thousands of patients and families affected by HIV and AIDS and the people who cared for them. This graphic novel combines Czerwiec’s memories with the oral histories of patients, family members, and staff. It... View Details


100 Questions & Answers About HIV and AIDS
by Joel E. Gallant (Author)

Whether you're a newly diagnosed patient or a friend or relative of someone suffering from HIV or Aids, this book can help. Offering both doctor and patient perspectives, 100 Questions & Answers About HIV and Aids, Third Edition provides authoritative and practical answers to the most commonly asked questions by patients and their loved ones. What is the difference between HIV and Aids? How can HIV infection be prevented? How do I find the right medical care?

Along with the answers to these and other questions, this book provides information on diagnosis, treatment, living with HIV and... View Details


Living with HIV: A Patient's Guide, 2D Ed. (Mcfarland Health Topics)
by Mark Cichocki RN (Author)

In its updated and expanded second edition, this helpful guide offers a wealth of information for people living with HIV and for people caring for HIV-positive loved ones. All aspects of HIV/AIDS are discussed, including opportunistic and associated infections, dental care, exercise and nutrition, substance use and abuse and emotional treatment. New information will help the newly diagnosed adjust to their illness and long-term survivors to improve their quality of life. Up-to-date discussion of the latest medications covers the growing practice of using HIV drugs as preventatives. Essential... View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Inspire To Action
What motivates us to take up a cause, follow a leader, or create change? This hour, TED speakers explore stories of inspirational leadership, and what makes some movements more successful than others. Guests include high school history teacher Diane Wolk-Rogers, writer and behavioral researcher Simon Sinek, 2016 Icelandic presidential candidate Halla Tómasdóttir, professor of leadership Jochen Menges, and writer and activist Naomi Klein.
Now Playing: Science for the People

#474 Appearance Matters
This week we talk about appearance, bodies, and body image. Why does what we look like affect our headspace so much? And how do we even begin to research a topic as personal and subjective as body image? To try and find out, we speak with some of the researchers at the Centre for Appearance Research (CAR) at the University of the West of England in Bristol. Psychology Professor Phillippa Diedrichs walks us through body image research, what we know so far, and how we know what we know. Professor of Appearance and Health Psychology Diana Harcourt talks about visible...